Add Formweb to your mobile device
Approved Formulary
Search results for:
trandolapril-verapamil
trandolapril-verapamil
- Restricted Medications Non-Formulary / Not-stocked
Brand names: Tarka
No brands, forms, or strengths have been added for this generic.
Display Class IV Antiarrhythmics, Vasodilating Agents, Miscellaneous, Calcium-Channel Blocking Agents, Angiotensin-Converting Enzyme Inhibitors Class:
24040424, 241292, 242800, 243204
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | trandolapril-verapamil (Tarka) |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | non-dihydropyridine calcium channel blockers (CCBs) ⇄ Heart failure |
| Rationale | Potential to promote fluid retention and/or exacerbate heart failure. |
| Recommendation | Avoid in heart failure with reduced ejection fraction. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | RAS inhibitors (ACEIs ARBs, ARNIs, aliskiren) ⇄ Another RAS inhibitor or a potassium-sparing diuretic |
| Risk Rationale | Increased risk of hyperkalemia. |
| Recommendation | Avoid routinely using 2 or more RAS inhibitors, or a RAS inhibitor and potassium-sparing diuretic, concurrently in those with chronic kidney disease Stage 3a or higher. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics | |
|---|---|
| Medication: | trandolapril-verapamil (Tarka) |
| Key Potentially Inappropriate Drugs in Pediatrics (KIDs) List: Second Edition (Table 1) | |
| Drug | verapamil |
| Risk/Rationale | Cardiovascular collapse |
| Recommendation | Caution in younger than 1 yr |
| Quality of evidence: Low, Strength of Recommendation: Weak | |
Last updated: Sep. 25, 2025